



1646#6  
DB  
4/4/01  
Dkt. 57155-D/JPW/ADM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christophe P.G. Gerald et al.  
U.S. Serial No. : 09/538;036  
Filed : March 29, 2000  
For : DNA ENCODING MAMMALIAN NEUROPEPTIDE FF  
(NPFF) RECEPTORS AND USES THEREOF

1185 Ave of the Americas  
New York, New York 10036  
March 29, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

APR 04 2001

Sir:

TECH CENTER 1600/2900

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Second Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(b)(3) to supplement the Information Disclosure Statements filed on March 29, 2000, and October 18, 2000.

Applicants submit this Second Supplemental Information Disclosure Statement in accordance with their duty of disclosure under 37 C.F.R. §1.56 in connection with the above-identified application.

According to 37 C.F.R. §1.97(b)(3), an Information Disclosure Statement shall be considered by the U.S. Patent and Trademark Office if filed before the mailing of a first Office Action on the merits. Applicants are filing this Second Supplemental Information Disclosure Statement before the issuance of a first Office Action on the merits.

Christophe P.G. Gerald et al.  
Serial No.: 09/538,036  
Filed: March 29, 2000  
Page 2

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following reference which is listed on the attached Form PTO-1449 (**Exhibit 1**). The following reference was previously cited in connection with the prosecution of U.S. Serial No. 09/255,368 from the filing date of which the subject application claims benefit under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, a copy of the reference is not attached to this Information Disclosure Statement.


1. PCT International Publication WO 00/29441, published May 25, 2000.

If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Christophe P.G. Gerald et al.  
Serial No.: 09/538,036  
Filed: March 29, 2000  
Page 3


No fee is deemed necessary in connection with the filing of this Second Supplemental Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Ave of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents,  
Washington, D.C. 20231.

 3/29/01  
John P. White  
Reg. No. 28,678

Date